![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.75 | 1.70 | 1.80 | 1.75 | 1.75 | 1.75 | 274,932 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.34 | 13.57M |
Date | Subject | Author | Discuss |
---|---|---|---|
17/6/2019 09:52 | Tick tock to 27 July, looking for another opportunity to top up here. Took a stake in (C4XD) recently, rising on a telegraph write up, let’s hope it follows this share price chart! | ![]() ny boy | |
13/6/2019 12:39 | Not sure if any of the regulars are going, no doubt we will hear more later. | ![]() ny boy | |
13/6/2019 11:34 | Be interested in comments on what’s coming out of the Norgine sales effort in Germany. 6 months of effort should have yielded something. | crankyman | |
13/6/2019 11:31 | No idea, haven’t heard anything, says on their web site it’s over 2 days 13-14 June? | ![]() ny boy | |
13/6/2019 08:10 | NY do you think anything might come out of today's agm, ? | ![]() wuzy | |
13/6/2019 07:55 | FDA decision fast closing in... only 32 trading days to go! | ![]() ny boy | |
11/6/2019 22:31 | Slow grind higher, anyone that wanted to cash in has probably already done so! Should get a bit perky last week or so before FDA decision | ![]() ny boy | |
11/6/2019 21:05 | From the chart it looks like the rise has stalled temporarily. I hope I am wrong but anyway I am sure normal service will be resumed shortly | ![]() nobbygnome | |
11/6/2019 20:53 | You are probably correct Montyhedge but I still think this is a very conservative view. Pharma shares with this IP must eventually be around 1000p. It might take a year but if they can fight off a buy out I am sure that the potential of the product to dominate the US and China market must be massive. My guess is the current graph profile will continue. Onwards and upwards. My £20k initial investmentlooks good. | maximus72 | |
11/6/2019 20:48 | >> az4hr I know nothing about either of the companies. Sorry. | ![]() nobbygnome | |
11/6/2019 15:21 | Monty was that your sell... 8 shares @ 115p? 😁 | ![]() ny boy | |
11/6/2019 11:41 | az4hr I bought a few C4XD today, early days but a decent pull back. Don’t know about the other stock. Tick tick here to 27 July | ![]() ny boy | |
11/6/2019 10:08 | 150p before 27th July should have a run up, seems deals all lined up, if approved, the US the biggest market, to me it's a given, I see 275p if not I see 85p. That's my view. | ![]() montyhedge | |
11/6/2019 09:03 | Should trade in a 110-150p trading range me thinks. I guess any spike closer to 27 July may suggest rumors of a leak | ![]() ny boy | |
10/6/2019 23:27 | Nobby have you looked at 4d pharma or c4xd do you have any opinions on them two thanks azhar | ![]() az4hr | |
10/6/2019 21:11 | I agree. If the deal is similar to the Norgine deal (or better), then surely it will be cheaper for the licensee to take STX out especially if the price is still languishing below £2. This includes taking into account the royalties they will pay over the next ten years. | ![]() nobbygnome | |
10/6/2019 21:07 | I personally would not worry to much about pricing in other European countries because if we get the right FDA result this company will get taken out. I just can’t see it not happening it’s just a case of who is bidding which will dictate The premium but minimum 3-4times current valuation. | ![]() best1467 | |
10/6/2019 19:07 | Peel Hunt restated their buy rating on shares of Shield Therapeutics (LON:STX) in a research report sent to investors on Monday, June 3rd, ThisIsMoney.Co.Uk reports. A number of other research analysts have also recently commented on STX. Liberum Capital reaffirmed a buy rating on shares of Shield Therapeutics in a research report on Monday, March 4th. FinnCap initiated coverage on Shield Therapeutics in a research report on Tuesday, May 14th. They set a corporate rating and a GBX 200 ($2.61) price target on the stock. | ![]() ny boy | |
10/6/2019 13:14 | Good advice NYboy. These Gordon Gekko wannabes are getting mugged every time. | maximus72 | |
10/6/2019 13:13 | Took a few more | ![]() volsung | |
10/6/2019 09:20 | Not long to go before take off. | ![]() montyhedge | |
10/6/2019 08:29 | The Teva appeal is of no real consequence for the medium term. There is only any possible effect after 2029! There is loads of money to be made by Shield and their licensees before then. I know the market discounts into the future..but not quite for 10 years! | ![]() nobbygnome | |
10/6/2019 08:24 | Buy those mini dips Sir, rinse & repeat since 20p’s, each time PI’s have had their shares stolen from them 🤦🏻 | ![]() ny boy | |
08/6/2019 11:55 | The £1000 TEVA appeal. | ![]() peachie 74 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions